The initial results of the IMbrave050 trial raised hopes that an efficient adjuvant regimen for hepatocellular carcinoma (HCC) would possibly possibly moreover ultimately maintain arrived. Patients with HCC treated with a combination of the immune checkpoint inhibitor atezolizumab and angiogenesis inhibitor bevacizumab after resection or ablation showed a 28% boost in recurrence-free survival at a medium apply-up of …
Read Extra
2024-09-18
